Skip to main content

Accelrys Non-compliant with Nasdaq Listing Rule

NEW YORK (GenomeWeb News) – Accelrys said on Friday that it has been notified by Nasdaq that the company does not comply with a listing requirement that its audit committee be comprised of three independent directors.

The San Diego-based firm received written notification from Nasdaq on June 4, Accelrys said in a document filed with the US Securities and Exchange Commission. The non-compliance results from Kenneth Coleman's decision not to seek re-election to the company's board for personal reasons. Coleman is a member of Accelrys' audit committee and his decision leaves the firm short of Nasdaq's three-person requirement.

Accelrys has until the company's next shareholder meeting on May 30, 2014 to provide evidence to Nasdaq that it fulfills the listing requirement. If the shareholder meeting is held before Nov. 26, 2013, Accelrys has until that date to provide its evidence, though Accelrys said it doesn't have plans to hold its shareholder meeting before Nov. 26.

It is currently identifying candidates to replace Coleman, Accelrys said.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.